Biodesix Details Lung Test Momentum, 81% Gross Margin and Growth Plan at Barclays Conference [Yahoo! Finance]
Biodesix, Inc. (BDSX)
Company Research
Source: Yahoo! Finance
decisioning and treatment guidance, and the company is expanding from pulmonology into primary care referral networks. Biodesix reported 81% gross margins for the prior year and reached adjusted EBITDA profitability in Q4, while citing rising average selling prices, improving commercial payer momentum, and a growing salesforce (from ~65 to ~100 with ~25 more planned) to drive sustainable cash-flow positivity. The services business and partnerships (e.g., Bio-Rad) are driving higher backlog and operating leverage, and the pipeline includes an MRD+proteomic test with Memorial Sloan Kettering, VeriStrat expansion into other tumor types, and "digital diagnostics" using imaging inputs. Interested in Biodesix, Inc.? Here are five stocks we like better. Biodesix (NASDAQ:BDSX) is focused on developing diagnostic tests intended to improve patient outcomes by answering specific clinical questions, Chief Financial Officer Robin Cowie said at a Barclays event. Commercially, the company's
Show less
Read more
Impact Snapshot
Event Time:
BDSX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BDSX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BDSX alerts
High impacting Biodesix, Inc. news events
Weekly update
A roundup of the hottest topics
BDSX
News
- Biodesix Announces the Largest Lung Nodule Biomarker Clinical Validation Study Ever Published Supporting Earlier Lung Cancer Diagnosis [Yahoo! Finance]Yahoo! Finance
- Biodesix Announces the Largest Lung Nodule Biomarker Clinical Validation Study Ever Published Supporting Earlier Lung Cancer DiagnosisGlobeNewswire
- Biodesix, Inc. (BDSX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
- Biodesix Details Lung Nodule Growth Plan, Primary Care Push at TD Cowen Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Are Medical Stocks Lagging Biodesix (BDSX) This Year? [Yahoo! Finance]Yahoo! Finance
BDSX
Earnings
- 2/26/26 - Beat
BDSX
Sec Filings
- 2/26/26 - Form 10-K
- 2/26/26 - Form 8-K
- 2/23/26 - Form 4
- BDSX's page on the SEC website